Find below videos and webinars on myeloma. Click here to check full educational resources materials for all areas of work: myeloma and AL amyloidosis, access, patient evidence and capacity building and advocacy.
ASH 2025 | IFM2021 01 trial

Now Playing
ASH 2025 | IFM2021 01 trial
Dr.Salomon Manier, University of Lille, France, talks through this ...
Dr.Salomon Manier, University of Lille, France, talks through this teclestameb trial. This study shows that an “all-antibody–based” doublet regimen of teclistamab and daratumumab is highly effective and well-tolerated in elderly ...newly diagnosed myeloma patients.Show More

Now Playing
ASH 2025 | Cobra trial
COBRA is a clinical trial evaluating carfilzomib, lenalidomide and ...
COBRA is a clinical trial evaluating carfilzomib, lenalidomide and dexamethasone (KRd) versus bortezomib, lenalidomide
and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma (NDMM). Watch this interview with Dr. Dominik ...Dytfeld, lead author of this study that was presented in the American Society of Hematology (ASH), held in Orlando, Florida, US.Show More
and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma (NDMM). Watch this interview with Dr. Dominik ...Dytfeld, lead author of this study that was presented in the American Society of Hematology (ASH), held in Orlando, Florida, US.Show More

Now Playing
ASH 2025 | LINKER-MM4 trial
Dr. Xavier Leleu, Centre Hospitalier Universitaire de Poitiers, ...
Dr. Xavier Leleu, Centre Hospitalier Universitaire de Poitiers, France, explains the main results of the LINKER-MM4 clinical trial which evaluates safety and efficacy of linvoseltamab as a simplified monotherapy in ...first-line regimen in
newly diagnosed myeloma patients. The initial results of this study were presented at the American Society of Heamtology (ASH) Annual Congress, held in Orlando, Florida, US.Show More
newly diagnosed myeloma patients. The initial results of this study were presented at the American Society of Heamtology (ASH) Annual Congress, held in Orlando, Florida, US.Show More

Now Playing
ASH 2025 | UK MRA FiTNEss trial
The UK MRA FiTNEss trial aims to understand whether the International ...
The UK MRA FiTNEss trial aims to understand whether the International Myeloma Working Group (IMWG) frailty score can be used to tailor treatment according to a myeloma patient’s level of ...fitness. Dr. Charlotte Pawlyn, from The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, UK, explains the main results of this trial, which were presented at the American Society of Hematology 2025.Show More

Now Playing
ASH25 | Majestec-3 trial
Watch Dr. Charlotte Pawlyn from The Royal Marsden NHS Foundation Trust ...
Watch Dr. Charlotte Pawlyn from The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, UK, explain the main results of Majestec-3, one of the most important ...myeloma studies presented at the American Society of Hematology (ASH) Annual Congress in Orlando, Florida, US.Show More

Now Playing
ASH 2025 | inMMyCAR trial
Dr. Phoebe Joy Ho from the Royal Prince Alfred Hospital and the ...
Dr. Phoebe Joy Ho from the Royal Prince Alfred Hospital and the University of Sydney, Australia, explains the results of inMMyCAR, a late breaking abstract presented at the American Society ...of Hematology (ASH) Annual Congress, held in Orlando, Florida, US.
The abstracts evaluates Minimal Residual Disease (MRD) negativity following a novel "in vivo" CAR T-cell therapy.Show More
The abstracts evaluates Minimal Residual Disease (MRD) negativity following a novel "in vivo" CAR T-cell therapy.Show More

Now Playing
ASH 2025 | DURGA 1 trial
The Durga-1 trial evaluates safety and efficacy of AZD0120, a ...
The Durga-1 trial evaluates safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma. Dr. Shambavi Richard, Icahn School of Medicine at Mount Sinai, New ...York, United States, explains the main results of the study and its implications for relapsed/refractory myeloma patients.Show More

Now Playing
ASH 2025 | CAMMA 3 clinical trial
Dr. Phoebe Joy Ho, Royal Prince Alfred Hospital and University of ...
Dr. Phoebe Joy Ho, Royal Prince Alfred Hospital and University of Sydney, Australia, explains for Myeloma Patients Europe (MPE) the first results from the phase Ib CAMMA 3 study, in ...which subcutaneous cevostamab shows manageable safety and meaningful clinical activity in relapsed/refractory myeloma (RRMM).
This clinical trial was presented at the American Society of Hematology (ASH) Annual Congress 2025, held in Orlando, Florida, US.Show More
This clinical trial was presented at the American Society of Hematology (ASH) Annual Congress 2025, held in Orlando, Florida, US.Show More

Now Playing
ASH 2025 | NoMoreMGUS
Dr. Bruno Paiva explains the main results of the NoMore MGUS clinical ...
Dr. Bruno Paiva explains the main results of the NoMore MGUS clinical trials presented at the American Society of Hematology (ASH) Annual Congress, in Orlando, Florida, US.

Now Playing
ASH 2025 | GEM-CESAR trial
Dr. Bruno Paiva, Clínica Universidad de Navarra, explains the main ...
Dr. Bruno Paiva, Clínica Universidad de Navarra, explains the main results of the GEM-CESAR clinical trial presented at the American Society of Hematology (ASH), held in Orlando, Florida, US.

Now Playing
Webinar EYMPG | Side effects and management of myeloma treatment
This webinar, organised by the MPE European Young Myeloma Patient ...
This webinar, organised by the MPE European Young Myeloma Patient Group (EYMPG), was given by Dr. Charlotte Pawlyn is a Clinician Scientist and Team Leader at the Institute of Cancer ...Research and an Honorary Consultant Haematologist at The Royal Marsden Hospital in London, UK.Show More

Now Playing
MPE webinar Myeloma and infection
Myeloma and infection: clinical and lived perspectives" was hosted by ...
Myeloma and infection: clinical and lived perspectives" was hosted by MPE and recorded on Thursday, 11th September 2025 from 17:00 – 18:00 CEST.
The webinar features a presentation from Jackie Quinn, ...Myeloma Clinical Nurse Specialist, Belfast Trust on how myeloma and treatments increase infection risk, covering immunisations, bispecific antibody risks, and preventive medications. You can also hear the story of Mimi Quinn, a myeloma patient from Ireland who shares her personal experience of infections during diagnosis and treatment, discussing how reduced immunity impacts her daily life and career.
The session concluded with a moderated Q&A where participants could ask questions.Show More
The webinar features a presentation from Jackie Quinn, ...Myeloma Clinical Nurse Specialist, Belfast Trust on how myeloma and treatments increase infection risk, covering immunisations, bispecific antibody risks, and preventive medications. You can also hear the story of Mimi Quinn, a myeloma patient from Ireland who shares her personal experience of infections during diagnosis and treatment, discussing how reduced immunity impacts her daily life and career.
The session concluded with a moderated Q&A where participants could ask questions.Show More

Now Playing
European Young Myeloma Patients Group | Latest developments in treatments for young myeloma patients
Recording of the webinar "Latest developments in treatments for young ...
Recording of the webinar "Latest developments in treatments for young myeloma patients" organise by the MPE European Young Myeloma Patients Group. The webinar was given by Prof. Dr. Michel Delforge ...of the Department of Haematology at the University Hospital Leuven.Show More

Now Playing
MPE Webinar | EHA 2025 highlights
Recording of the webinar organised to summarise the most important ...
Recording of the webinar organised to summarise the most important myeloma updates presented at the European Hematology Association (EHA) Annual Congress 2025, held in Milan, Italy.

Now Playing
EHA 2025 | Shared Decision-Making (SDM)
The MPE Head of Patient Research, Eilidh Duncan, presented the results ...
The MPE Head of Patient Research, Eilidh Duncan, presented the results of our Shared Decision-Making (SMD) research. In this video interview, Eilidh explains the key aspects, challenges and recommendations of ...this concept.Show More
1
of 11